mProX™ Human SLC34A2 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

SLC34A2 is a gene that plays a role in various medical conditions. In the context of non-small cell lung cancer (NSCLC), SLC34A2 gene fusions can be detected using RNA-based next-generation sequencing (NGS) assays. This study found that RNA-based NGS had a high concordance rate with fluorescence in situ hybridization (FISH) testing for detecting ALK, RET, and ROS1 fusions in NSCLC cytology specimens. However, RNA-based NGS had a high failure rate, so additional testing methods may be necessary for comprehensive genomic profiling. In the case of pulmonary alveolar microlithiasis (PAM), a rare lung disease, SLC34A2 gene mutations are implicated. PAM is characterized by the presence of calcified microliths in the lungs and can be diagnosed through radiological examination, SLC34A2 mutation analysis, or the presence of microliths in bronchoalveolar lavage or sputum. Lung transplantation is currently the only effective treatment for PAM. Additionally, SLC34A2 is involved in intestinal phosphate absorption, particularly in young mice, where increased expression of SLC34A2 and paracellular phosphate permeability contribute to higher intestinal phosphate absorption.